These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32038663)

  • 1. Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients.
    Pilon C; Bigot J; Grondin C; Thiolat A; Lang P; Cohen JL; Grimbert P; Matignon M
    Front Immunol; 2020; 11():34. PubMed ID: 32038663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.
    Matignon M; Pilon C; Commereuc M; Grondin C; Leibler C; Kofman T; Audard V; Cohen J; Canoui-Poitrine F; Grimbert P
    PLoS One; 2017; 12(6):e0178572. PubMed ID: 28654684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
    Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
    Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction.
    Cooper JE; Gralla J; Klem P; Chan L; Wiseman AC
    Transplantation; 2014 Jun; 97(12):1253-9. PubMed ID: 24937199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion.
    Solgi G; Pourmand G; Mehrsai A; Taherimahmoudi M; Nicknam MH; Ebrahimi Rad MR; Seraji A; Asadpoor A; Ansaripor B; Nikbin B; Amirzargar A
    Iran J Immunol; 2010 Mar; 7(1):18-29. PubMed ID: 20371916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
    Lefaucheur C; Viglietti D; Hidalgo LG; Ratner LE; Bagnasco SM; Batal I; Aubert O; Orandi BJ; Oppenheimer F; Bestard O; Rigotti P; Reisaeter AV; Kamar N; Lebranchu Y; Duong Van Huyen JP; Bruneval P; Glotz D; Legendre C; Empana JP; Jouven X; Segev DL; Montgomery RA; Zeevi A; Halloran PF; Loupy A
    J Am Soc Nephrol; 2018 Feb; 29(2):620-635. PubMed ID: 29042454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
    Abuhelaiqa E; Friedlander R; Aull M; Putheti P; Sharma V; Suthanthiran M; Dadhania D
    Clin Transpl; 2016; 32():83-91. PubMed ID: 28564525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
    Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
    Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
    Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
    Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
    Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers.
    Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Avila Bernabeu A; Crespo Albiach J; Molina Vila P; Beltrán Catalan S; Pallardó Mateu L
    Transplant Proc; 2016 Nov; 48(9):2880-2883. PubMed ID: 27932097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
    Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
    Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.